Description
Rysomep is a highly effective proton pump inhibitor formulated with Esomeprazole 40 mg per capsule, designed to provide long-lasting relief from acid-related gastrointestinal disorders. Indicated for conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, gastric ulcers, and Zollinger-Ellison syndrome, Rysomep reduces gastric acid production by inhibiting the hydrogen-potassium ATPase enzyme in the gastric parietal cells.
Each pack contains 2 strips of 7 capsules (total 14 capsules), sealed in moisture-resistant blisters to preserve pharmaceutical integrity. Manufactured by ANVIS, the formulation meets international standards of quality and is suitable for adults under medical supervision. With once-daily dosing, Rysomep offers convenience and sustained symptom control, making it an ideal choice for both acute and chronic management of acid-peptic disorders.
Rysomep is recommended in hospital and outpatient settings where reliable acid suppression is required, particularly for patients who do not respond adequately to H2-receptor antagonists or require long-term therapy.
